4/17
02:33 pm
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $12.00 to $10.00. They now have a "neutral" rating on the stock.
Low
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $12.00 to $10.00. They now have a "neutral" rating on the stock.
4/9
08:09 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Medium
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
4/3
08:00 am
phat
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
High
Report
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
4/2
11:50 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Guggenheim.
4/2
08:11 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Medium
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
4/1
04:15 pm
phat
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/1
08:00 am
phat
Phathom Pharmaceuticals Announces Leadership Succession
High
Report
Phathom Pharmaceuticals Announces Leadership Succession
3/31
07:59 am
phat
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
Medium
Report
Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)
3/10
01:37 pm
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $18.00 to $12.00. They now have a "neutral" rating on the stock.
Low
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $18.00 to $12.00. They now have a "neutral" rating on the stock.
3/10
11:10 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Craig Hallum.
Medium
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Craig Hallum.
3/7
08:13 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
High
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
3/6
02:24 pm
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
Medium
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
3/6
09:38 am
phat
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
3/6
08:00 am
phat
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Medium
Report
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2/26
06:22 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
High
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
2/24
09:04 am
phat
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 [Yahoo! Finance]
Medium
Report
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 [Yahoo! Finance]
2/24
08:00 am
phat
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
Medium
Report
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
2/14
07:14 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $23.00 price target on the stock.
Low
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $23.00 price target on the stock.
2/9
02:09 pm
phat
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference [Yahoo! Finance]
High
Report
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference [Yahoo! Finance]
1/29
08:00 am
phat
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
Medium
Report
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference